olanzapine + risperidone

ApprovedCompleted
1 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Bipolar Disorder

Conditions

Bipolar Disorder

Trial Timeline

Aug 1, 2001 → Aug 1, 2002

About olanzapine + risperidone

olanzapine + risperidone is a approved stage product being developed by Eli Lilly for Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00034580. Target conditions include Bipolar Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Bipolar Disorder were approved

Approved (20) Terminated (3) Active (0)
Olanzapine + PlaceboEli LillyApproved
OlanzapineEli LillyApproved
OlanzapineEli LillyApproved
Topiramate + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00190749ApprovedCompleted
NCT00034580ApprovedCompleted

Competing Products

20 competing products in Bipolar Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
32
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyApproved
43
FK949EAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 3
40
FK949E + PlaceboAstellas PharmaPhase 2/3
38
Escitalopram + Bupropion XLLupin LimitedPhase 3
32
OlanzapineEli LillyApproved
43
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
40
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
OlanzapineEli LillyApproved
43
OlanzapineEli LillyPhase 3
40
LY2979165 + PlaceboEli LillyPhase 1
29
olanzapine + divalproex sodium + placeboEli LillyApproved
43
LY2979165 + placeboEli LillyPhase 1
29
Topiramate + PlaceboEli LillyApproved
43
olanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyPhase 3
40
Brenipatide + PlaceboEli LillyPhase 2
42
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
43